FTC chair Lina Khan to Senate: Big Pharma M&A is still a priority target

Zachary Brennan

Senior Editor

As the Federal Trade Commission has already sought new ideas for analyzing pharma mergers, FTC chair Lina Khan reiterated Tuesday to a Senate subcommittee that reviewing Big Pharma mergers is a priority.

While comparing this merger analysis in the pharma space to the study of public utilities in the 1930s “that exposed rampant financial fraud,” Khan said in prepared testimony that the commission is going to target unlawful conduct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

FTC chair Lina Khan to Senate: Big Pharma M&A is still a priority target

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

FTC chair Lina Khan to Sen­ate: Big Phar­ma M&A is still a pri­or­i­ty tar­get

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

FTC chair Lina Khan to Senate: Big Pharma M&A is still a priority target

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them